Mainz Biomed (MYNZ) zooms 58% higher after promising deal

January 05, 2022 08:22 PM CET | By Rupam Roy
 Mainz Biomed (MYNZ) zooms 58% higher after promising deal
Image source: Khakimullin Aleksandr,Shutterstock

Highlights

  • The company entered into a Technology Rights Agreement with Colombo’s Socpra Sciences Sante Et Humaines S.E.C.

  • Its revenue was US$0.41 million for the six months ended June 30, 2021.

  • The stock price surged more than 29% over the last month.

The stocks of Mainz Biomed (MYNZ) zoomed 58% higher on Wednesday after it brokered a deal with a Colombian institute to gain access to novel mRNA biomarkers for potential integration with its highly effective colorectal cancer (CRC) detection test called ColoAlert in the future.

The German-headquartered company said it has entered into a Technology Rights Agreement with Colombia’s Socpra Sciences Santé Et Humaines S.E.C.

The deal would help Mainz gain access to a collection of novel mRNA biomarkers for future integration with its user-friendly colorectal cancer (CRC) detection test ColoAlert.

Mainz is a molecular genetics diagnostic firm that specializes in detecting early-stage cancer.

Its flagship product is ColoAlert, currently marketed in Europe.

A clinical study is also in progress for ColoAlert in the US for FDA approval in 2022.

Also Read: The Great Resignation: Will it continue in 2022?

In Europe, it markets ColoAlert in partnership with third-party laboratories.

As per the deal, Mainz has the unilateral option to license exclusive global rights to five gene expression biomarkers that demonstrate a higher efficacy for detecting CRC lesions.

Reacting to the deal, Mainz CEO Guido Baechler said it is a great opportunity to upgrade ColoAlert's technical profile, which will make it the most effective at-home testing kit for CRC.

Also Read: Seven hottest IPOs to explore in 2022

Why did Mainz Biomed (MYNZ) stock soar on Wednesday?

Also Read: Top fake meat stocks to keep an eye on in 2022

Stock performance and financial highlights of Mainz Biomed B.V. (NASDAQ:MYNZ):


The MYNZ stocks were priced at U$16.44 at 11:14 am ET on Jan 5, up 58.23% from their previous close. Its market cap is US$181.97 million.

The stock gave a 29.07% return in the last 30 days.

Also Read: Why is Ribbon Finance (RBN) crypto in focus?

The stock saw the highest price of US$18.00 and the lowest price of US$7.80 in the last 52 weeks. Its trading volume on Jan 4 was 43,497.

For the six months ended June 30, 2021, it reported a revenue of US$0.41 million compared to US$0.16 million a year ago. Its net loss was US$0.26 million against a loss of US$0.34 million for the six months ended June 30, 2020.

Also Read: What is Helium (HNT) token? HNT crypto gains 2645% in 12 months

Bottomline

The stock saw steady gains in recent days. Overall, the healthcare sector has been in the spotlight due to the Covid-19 emergency. Investors, however, should exercise due diligence before investing in the stock market.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Sponsored Articles